top of page

About Timber Pharmaceuticals

Meet the Team

Timber is committed to developing treatments for unmet needs in medical dermatology. To deliver on our promise to you, our team is made of world class advisors and a strong leadership team with a proven track record of success.

John Koconis Headshotv2.jpg
John Koconis, MBA

John has had a highly accomplished career as both a strategic and operational leader in the pharmaceutical sector with over 25 years of experience leading successful teams in global markets and launching multiple market-leading products. John brings a unique perspective through his experience in broad, specialty and rare/orphan dermatology development and commercialization.

Joseph Lucchese

Joe is the Chief Financial Officer of Timber Pharmaceuticals as well as a Partner at TardiMed Sciences. Prior to joining TardiMed, he was a founding member and Managing Director of Oncology Partners, a boutique financial advisory firm serving development stage biotechnology companies and investors. Prior to founding Oncology Partners, Joe was a Managing Partner of Foundation Ventures, an investment banking firm servicing early stage life sciences companies.

Alan Mendelsohn, MD.png
Alan Mendelsohn, MD

Dr. Mendelsohn is Board certified in Pediatrics and Pediatric Cardiology. He has strong management skills, and has over 20 years of drug development and medical affairs experience with major pharmaceutical companies, including Sun Pharma, Pfizer, and Johnson & Johnson / Janssen.

Jess Bruno.png
Jessica Bruno-Raiz, MPH
VP Global Program Management and Clinical Operations

Over 20 years experience working in R&D with a proven track record of influencing global strategy for optimal clinical development. Jessica has held roles with increasing responsibilities within Clinical Development/ Clinical Operations where she spearheaded designing, developing and implementing innovative processes, best practice methodologies and strategic initiatives with the aim of identifying efficiencies and optimizing project outcomes

While at Novartis and GSK, led cross-functional teams focused on Phase II/III global clinical studies in Oncology and Rx to OTC switch. Jessica has also held positions in Learning and Development, allowing her to develop a curriculum to educate peers within R&D as well as a Process Improvement Manager with training in Lean Six Sigma.

bottom of page